How to Tell If NMN Is Working: The 3-Layer Signal Decoder (Trial Endpoints vs Body Feel vs Blood Tests)

You just finished your third bottle. Somewhere around month three, you did the math: $45 a month, 90 capsules swallowed, and the total sensory evidence that anything happened inside you is — nothing. No energy surge. No sleep upgrade. Skin looks the same. So the question that lands in the search bar at 11pm is the one this article answers directly: how to tell if NMN is working, or whether you've been paying for expensive urine.

Here's a data point that complicates the story. Under a YouTube video by Dr. Brad Stanfield (a GP who covers NAD+ research), a 67-year-old commenter reported taking NMN for a year, feeling absolutely nothing subjectively — and then watching a blood test show his NAD+ level had climbed dramatically. One anecdote, zero scientific weight on its own. But it frames the exact problem: "I feel nothing" and "it isn't working" are two different claims, and most people have no way to separate them.

That's what this article does. Instead of a verdict, you get a classification system — three layers of signals, each with its own evidence strength, its own measurement method, and its own realistic timeline. By the end you'll know which layer your particular signal belongs to, and what to actually measure if you want an answer instead of a vibe.

The Problem: NMN Works at a Level Your Feelings Can't Access

The primary documented action of NMN in humans is boring and invisible: it raises the concentration of NAD+ inside your cells. NAD+ is a coenzyme that sits at the center of energy metabolism and DNA repair machinery, and its concentration in tissues declines with age — this decline is one of the better-replicated biochemical findings in aging research (Yoshino et al., 2018).

Now ask yourself: what does "more NAD+ in my muscle mitochondria" feel like?

Nothing. There is no sensory receptor for intracellular coenzyme concentration. You cannot feel insulin sensitivity improving by a few percent. You cannot feel a modest shift in skeletal muscle insulin signaling — which is precisely what the first human NMN trial measured as its main outcome (Yoshino et al., 2021). These changes live below the floor of conscious perception.

So the honest starting position is a double negative:

• Not feeling anything ≠ it's not working. The mechanism operates in a place your nervous system has no readout for.
• Feeling something ≠ it's working. Expectation alone reliably produces reported benefits, and placebo groups in supplement trials report "more energy" too.

Both directions of the inference are broken. Which is why "does NMN actually do anything" can't be answered with feelings — only with signals sorted into layers.

Why "I Feel Nothing" Is the Most Common — and Least Informative — Report

Scan any NMN subreddit and "I feel nothing" posts outnumber "I feel it" posts by a wide margin. This is exactly what you'd predict from the mechanism. If the measurable effects in trials are things like whole-blood NAD+ concentration (Okabe et al., 2022) and muscle insulin sensitivity (Yoshino et al., 2021) — quantities measured with mass spectrometry and glucose clamps — then a healthy 45-year-old with no metabolic dysfunction should expect to feel approximately nothing, whether or not the supplement is doing its biochemical job.

The feeling channel and the mechanism channel are simply different channels. Layer 1 and Layer 3 below are where the real information lives.

Layer 1 — What Clinical Trials Actually Measure

If you want to know whether NMN is doing anything, the first question isn't "what do people report?" It's "what did researchers define as success?" Here's the endpoint sheet for the human randomized trials that get cited most — including the null results, because those matter just as much.

Read that table the way a trialist would, not the way a marketing page would:

1. The most replicated endpoint is blood NAD+ itself. Every trial above raised it. That's a pharmacokinetic fact, not a health benefit claim — it proves NMN reaches and moves the target, not that moving the target makes you healthier.

2. The functional results are thinner and concentrated in middle-aged and older adults. Grip and gait gains in Igarashi were labeled "nominally significant" by the authors themselves — a deliberately cautious phrase — and only 20 participants completed the 12-week arm. The 6-minute walk improvement in Yi 2023 is the strongest functional signal, in middle-aged adults. If you're in your 30s and healthy, none of these trials directly studied you.

3. The nulls are on the table. Okabe measured no functional endpoints at all — its only positive finding was NAD+ itself. Yi found HOMA-IR unchanged despite the walk improvement. Igarashi found no body-composition change. A supplement whose evidence includes honest null endpoints is a supplement you can actually reason about — and it means "no visible change" is a possible true outcome, not proof you bought a counterfeit.

That's Layer 1: the definition of "working" that researchers use. Now the layer everyone actually uses.

Layer 2 — Body Signals You Might Feel (and Why They're Placebo-Vulnerable)

People don't run glucose clamps on themselves. They notice energy, sleep, recovery after exercise, skin. These signals are real experiences — but they run through the least reliable instrument in the chain: a human brain that knows it just spent $45 and expects results.

Expectation shapes perception. Placebo groups in blinded supplement trials report fatigue and energy improvements across categories, and NMN studies are small enough that subjective reports were never their strong evidence anyway. This cuts both ways:

• The person who feels "clean energy" on day 3 may be experiencing expectation.
• The person who feels nothing at day 90 may be experiencing a real, sub-perceptual effect.

Feelings can't distinguish these cases. That's not a character flaw — it's the limit of the instrument.

The Reddit Debate: "Research Shows NMN Does Nothing?"

On r/NMN, a thread titled along the lines of "Research shows NMN does nothing?" (thread 16rv6zl) plays out the exact argument this article is trying to settle. One camp cites subjective reports — often "my sleep changed in 4 weeks" — as proof. The other camp cites null or modest trial outcomes as proof of nothing. Both camps commit the same category error: comparing a Layer 2 signal (subjective sleep quality) against Layer 1 signals (clamp-measured insulin sensitivity, spectrometry-measured NAD+) as if they were the same currency.

The thread is worth reading as community context — a genuine snapshot of how confused this conversation gets when layers get mixed. It is not medical evidence, and this article doesn't treat it as such.

Which Feelings Are Directionally Plausible vs Marketing Noise

Not all subjective signals are equally absurd. Sort them by whether the trials even gesture in that direction:

Directionally plausible (trials measured something adjacent):

• Physical performance in middle-aged and older adults — walking endurance, gait speed. Layer 1 trials measured exactly this (Yi 2023; Igarashi 2022). If you're past midlife and your walking stamina changed, that at least matches a measured endpoint.
• Exercise recovery — plausible mechanistically via NAD+'s role in energy metabolism, but human trial data here is thin. Treat as hypothesis, not finding.

Marketing noise (no human endpoint comes close):

• "Mode," "glow," "cellular regeneration vibes" — no trial has ever measured, or could measure, any of this. If a brand tells you to expect a "feeling," they're selling the feeling.
• Skin appearance — human NMN data here is minimal. Confident skin claims come from brands, not trials.
• Sleep quality — self-reported in some studies, placebo-vulnerable in all of them. If NMN noticeably changes your sleep, read why NMN can keep you awake at night before crediting the mechanism — timing effects can cut the wrong way.

The rule for Layer 2: a feeling can be a reason to measure. It is never, by itself, a verdict.

Layer 3 — Biomarkers You Can Actually Measure

This is the layer that converts the question from unanswerable to answerable. Two families of measurements, one paid and objective, one free and semi-objective.

At-Home NAD+ Blood Tests: What They Cost and What They Actually Tell You

At-home whole-blood NAD+ tests exist. The most established is Jinfiniti's Intracellular NAD test kit — a finger-prick blood spot you mail in, analyzed in a CLIA-certified lab, with results returned days after the lab receives your sample. The standalone kit has historically retailed in the roughly $100–200 range; check current pricing directly, because it shifts.

What the test genuinely tells you: whether your supplementation moved your whole-blood NAD+ concentration. This is the same endpoint family that Okabe and Igarashi measured in trials — meaning it's the one biomarker where home measurement and trial measurement actually connect.

What it doesn't tell you: whether that elevation is producing any health benefit. A higher number is a pharmacokinetic result. The trial table above shows the health-outcome layer sits on top of it, thinner and population-specific.

Two hard rules for using it:

1. Baseline first, always. A single number means almost nothing — reference ranges vary by lab and method, and no universally validated "you're healthy at X nmol/L" threshold exists that this article could verify against a primary source. Anyone quoting you a precise cutoff without specifying the lab method is overclaiming. What means something is your before-vs-after-8-to-12-weeks delta, run through the same lab.
2. Match the timeline to the trials. NAD+ elevation was documented at 6–12 weeks in trials (Igarashi 2022). Testing after 10 days wastes the money.

DIY Functional Tests: Baseline 6-Minute Walk, Stair Climb, Morning Resting HR

You can approximate Layer 1's functional endpoints at home, free, with a stopwatch:

• 6-minute walk test. Mark a flat course, walk as far as you comfortably can in 6 minutes, record the distance. This is a real clinical endpoint — the same one Yi 2023 used. Do it twice at baseline to learn your own noise; meaningful changes in trials were on the order of a few percent.
• Timed stair climb or 5 chair stands. Lower-limb function proxies in the same family as the gait endpoints trials used.
• Morning resting heart rate. Take it before getting up, same conditions daily, log a 7-day rolling average. Not an NMN endpoint per se, but a cheap, sensitive general signal.

None of these prove causation — life interferes, seasons change, some months you sleep worse. But they beat feelings, because they're numbers, and numbers can be compared to themselves.

Your Signal Classifier: Matching What You Notice to the Right Layer

Here's the second table. Take whatever you've noticed — or not noticed — and drop it into the right row. The point isn't a verdict on NMN; it's knowing which class of signal you're holding and how much weight it can carry.

Two honest readings fall out of this table. First, the signals people chase (energy, sleep) are the weakest signals available, and the strongest signals (blood NAD+, walk distance) are the ones almost nobody measures. Second, "I feel nothing" sits in the row that carries no information — it neither confirms nor refutes anything above it.

One complication worth flagging: if you're stacking NMN with resveratrol, you've added a second variable, and the classifier gets worse, not better — any signal you detect could belong to either compound. See the NMN + resveratrol stack guide for how to think about attribution before combining.

When to Stop: Honest Exit Criteria

The most expensive mistake isn't buying NMN. It's rebuying NMN indefinitely with no measurement, no baseline, and no stopping condition.

Run the arithmetic. At a typical $40–60 per month for a reputable product:

Monthly cost × 6 = your information bill.

$50/month × 6 months = $300 — spent over six months with zero Layer 3 data.

For roughly the same $300, you could have bought one at-home NAD+ test (~$100–150) and kept $150–200 of supplement budget — and actually learned something.

Six months of unmeasured supplementation buys you nothing you didn't have on day one. Six months with a baseline 6-minute walk, a morning HR log, and one before/after blood test buys you an answer — or the closest thing to one available outside a trial.

A reasonable exit protocol:

1. Before the first capsule: record your baseline — 6MWT (twice), morning resting HR (7-day average), optionally a baseline NAD+ blood test.
2. At 8–12 weeks: re-measure the same things the same way.
3. Decision point: if blood NAD+ moved but nothing else did, you now know you're a responder at the biochemical layer and can decide with open eyes whether that alone is worth $600/year. If you never measured anything and you're three bottles deep on feelings alone, don't buy bottle four. Either stop, or test first and then decide.

This is not a recommendation to quit, and not a recommendation to continue. It's a recommendation to replace an unanswerable question with a measurable one. If you're still choosing a product and want to compare purity and third-party testing before running your n-of-1, start with the best NMN supplements of 2026 — an underdosed or contaminated product makes every layer above moot.

The Bottom Line

Three layers, one system:

• Layer 1 tells you what "working" even means — blood NAD+, clamp-measured insulin sensitivity, walk distance. Trials have confirmed the first across the board; the functional endpoints are real but concentrated in older adults, with honest nulls on the record.
• Layer 2 — your feelings — is the weakest layer. Not fake, just structurally incapable of answering the question, in either direction.
• Layer 3 is where you get an actual answer: baseline, re-test at 8–12 weeks, compare your numbers to your numbers.

Feeling nothing is not failure. But feeling nothing while refusing to measure is a choice to stay in the dark, and at $40–60 a month, the dark is expensive. Tonight, before your next dose: time a 6-minute walk, take your resting heart rate in bed tomorrow morning, write both down. In twelve weeks you'll know more than three empty bottles ever told you.

References

1. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism, 2018. PMID 29249689. — https://pmc.ncbi.nlm.nih.gov/articles/PMC5842119/
2. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in postmenopausal women with prediabetes and obesity. Science, 2021. PMID 33888596. — https://pmc.ncbi.nlm.nih.gov/articles/PMC8550608/
3. Okabe K, Yaku K, Uchida Y, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy older subjects. Frontiers in Nutrition, 2022. PMID 35479740. — https://pubmed.ncbi.nlm.nih.gov/35479740/
4. Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj Aging, 2022. PMID 35927255. — https://pubmed.ncbi.nlm.nih.gov/35927255/
5. Yi L, Maier AB, Tao R, et al. The efficacy of oral nicotinamide mononucleotide supplementation on muscle performance in older adults: a randomized, double-blind, placebo-controlled trial. GeroScience, 2023. PMID 36482258. — https://pubmed.ncbi.nlm.nih.gov/36482258/